Topic desk · 2 reviewed briefs
Melanocortin peptide medicines
Understand how two approved melanocortin medicines can have narrow, unrelated indications without validating broad tanning or performance claims.
Evidence boundary
Approval of one analogue and product does not transfer to another molecule, route, population, or cosmetic promise.
- Reviewed briefs
- 2
- Established contexts
- 2
- Reviewed claims
- 6
Before accepting a claim
Ask the question the promotion leaves out.
- 01
Which melanocortin receptor and product are involved?
- 02
What exact condition and endpoint were studied?
- 03
Is a narrow indication being rewritten as a universal enhancement claim?
Connected briefs
Compare evidence without flattening it.
Approved human outcomesEstablished for reviewed context
Bremelanotide
An approved melanocortin medicine for a defined sexual-desire disorder, not a general sexual-performance enhancer.
3 reviewed claims · Open brief ↗Approved human outcomesEstablished for reviewed context
Afamelanotide
An approved implant that increases pain-free light exposure in adults with EPP, not a general-purpose tanning or cosmetic peptide.
3 reviewed claims · Open brief ↗